Barclays Maintains Overweight on RXO, Raises Price Target to $28

Benzinga Newsdesk www.benzinga.com Positive 73.9%

Neg 0% Neu 0% Pos 73.9%

Barclays analyst Brandon Oglenski maintains RXO (NYSE:RXO) with a Overweight and raises the price target from $20 to $28.